Qiagen (NYSE:QGEN – Get Free Report)’s share price reached a new 52-week low on Wednesday after JPMorgan Chase & Co. lowered their price target on the stock from $55.00 to $50.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Qiagen traded as low as $38.13 and last traded at $38.22, with a volume of 311147 shares traded. The stock had previously closed at $38.91.
A number of other brokerages have also issued reports on QGEN. TheStreet lowered shares of Qiagen from a “b-” rating to a “c+” rating in a research note on Thursday, September 14th. Citigroup reissued a “buy” rating and issued a $60.00 target price on shares of Qiagen in a research report on Tuesday, September 26th. HSBC dropped their price target on Qiagen from $64.00 to $57.00 in a research note on Friday, September 29th. UBS Group reduced their price objective on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Wednesday, August 9th. Finally, StockNews.com began coverage on Qiagen in a report on Thursday, October 5th. They set a “buy” rating for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Qiagen presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.27.
Check Out Our Latest Stock Report on QGEN
Hedge Funds Weigh In On Qiagen
Qiagen Stock Down 2.7 %
The business’s fifty day simple moving average is $41.79 and its two-hundred day simple moving average is $44.26. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.36 and a quick ratio of 1.96. The company has a market cap of $8.63 billion, a PE ratio of 25.74, a PEG ratio of 9.47 and a beta of 0.40.
Qiagen (NYSE:QGEN – Get Free Report) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.01. The company had revenue of $497.00 million during the quarter, compared to analysts’ expectations of $492.21 million. Qiagen had a return on equity of 13.72% and a net margin of 17.04%. Qiagen’s quarterly revenue was down 8.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.51 EPS. On average, analysts predict that Qiagen will post 2.07 earnings per share for the current year.
About Qiagen
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Recommended Stories
- Five stocks we like better than Qiagen
- How to Invest in EV Charging Stations
- Dollar Tree Won’t Be Trading At a Discount For Much Longer
- How to Invest in Solar Energy
- ASML Holding is a Great Buy but at a Cheaper Price
- The How and Why of Investing in Gold Stocks
- Oversold and Overextended, Abbott Laboratories is a Great Buy
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
